Lexaria Bioscience Corp. announced the exercise of warrants for 453,969 shares at a reduced price of $12.92 per share, raising approximately $5.9 million in gross proceeds. The funds will support the company's working capital and general corporate purposes, including research and development programs in 2027. This transaction follows a recent $2.6 million tax rebate from the Australian Tax Office. New unregistered Series A and B warrants will also be issued as part of the deal, with registration filings planned for the resale of shares.
Arizona Gold & Silver announced new drill results from its Philadelphia gold-silver project in Arizona, revealing broad zones of gold mineralization with higher-grade intervals in three Perry Zone infill holes. The drilling confirmed continuity and s...
Meta Platforms is transitioning from a light to a heavy asset model by investing aggressively in AI infrastructure. Despite investor doubts about the return on AI investments and a decline in free cash flow, Meta trades at a forward price-to-earnings...
Nvidia recently surpassed a $5 trillion market capitalization, driven by over 100% revenue growth and strong data center demand. Analysts see further upside, with a price target around $301, implying a 32.65% gain, fueled by the Vera Rubin product ra...
Celestica has increased its 2026 revenue forecast to $20.5 billion and EPS to $11.30, driven by strong AI infrastructure demand. Q3 growth neared 69% year-over-year, supported by extended component lead times and binding commitments that provide visi...
Ocumetics has begun recruiting patients in Mexico City for Group Two of its human clinical study, targeting surgeries in Fall 2026. This phase will assess the safety and vision performance of its next-generation accommodating intraocular lens, buildi...
